Viridian Therapeutics’ (VRDN) “Buy” Rating Reiterated at Needham & Company LLC
MarketBeatNeedham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Monday.
Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Monday.